Floatz logo

2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-

Alkylating Agent-Related Acute Myeloid Leukemia

National Cancer Institute (NCI)Small moleculePhase 3Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Alkylating Agent-Related Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Azacitidine
National Cancer Institute (NCI)
Phase 2BB
Fluconazole
Children's Oncology Group
Phase 3BB
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 2BB
CASPOFUNGIN
Children's Oncology Group
Phase 3BB
cc-5013
M.D. Anderson Cancer Center
Phase 2B

View all 20 →

Same molecule, other indications

2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- is also rated in:

acute monocytic leukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
acute megakaryoblastic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
acute myeloid leukemia with minimal differentiationDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →